[{"address1": "259 Liberty Avenue", "city": "Staten Island", "state": "NY", "zip": "10305", "country": "United States", "phone": "917 533 1469", "website": "https://www.acurxpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert J. DeLuccia", "age": 77, "title": "Co-Founder & Executive Chairman", "yearBorn": 1946, "fiscalYear": 2023, "totalPay": 701536, "exercisedValue": 0, "unexercisedValue": 15167}, {"maxAge": 1, "name": "Mr. David P. Luci CPA, Esq., J.D.", "age": 56, "title": "Co-Founder, President, CEO, Corporate Secretary & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 668978, "exercisedValue": 0, "unexercisedValue": 15167}, {"maxAge": 1, "name": "Mr. Robert G. Shawah CPA, CPA", "age": 56, "title": "Co-Founder & CFO", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 470288, "exercisedValue": 0, "unexercisedValue": 8750}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.13, "open": 2.13, "dayLow": 2.1, "dayHigh": 2.141, "regularMarketPreviousClose": 2.13, "regularMarketOpen": 2.13, "regularMarketDayLow": 2.1, "regularMarketDayHigh": 2.141, "beta": -1.716, "forwardPE": -1.3741937, "volume": 37416, "regularMarketVolume": 37416, "averageVolume": 58653, "averageVolume10days": 71320, "averageDailyVolume10Day": 71320, "bid": 2.1, "ask": 2.16, "bidSize": 400, "askSize": 200, "marketCap": 34602064, "fiftyTwoWeekLow": 1.17, "fiftyTwoWeekHigh": 8.82, "fiftyDayAverage": 2.17632, "twoHundredDayAverage": 2.73618, "currency": "USD", "enterpriseValue": 28078752, "floatShares": 13840499, "sharesOutstanding": 16245100, "sharesShort": 439435, "sharesShortPriorMonth": 561166, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0271, "heldPercentInsiders": 0.14802, "heldPercentInstitutions": 0.11886, "shortRatio": 5.41, "shortPercentOfFloat": 0.0318, "impliedSharesOutstanding": 16245100, "bookValue": 0.214, "priceToBook": 9.953272, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -16729286, "trailingEps": -1.16, "forwardEps": -1.55, "52WeekChange": 0.19774008, "SandP52WeekChange": 0.24014747, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ACXP", "underlyingSymbol": "ACXP", "shortName": "Acurx Pharmaceuticals, Inc.", "longName": "Acurx Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1624627800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f968c125-b6b8-3075-a306-c4b0f5d5bed0", "messageBoardId": "finmb_558025934", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.13, "targetHighPrice": 12.0, "targetLowPrice": 10.0, "targetMeanPrice": 11.26, "targetMedianPrice": 11.77, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 6360858, "totalCashPerShare": 0.392, "quickRatio": 2.034, "currentRatio": 2.087, "returnOnAssets": -1.3221699, "returnOnEquity": -3.46942, "freeCashflow": -5961016, "operatingCashflow": -12234498, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]